Currently, there are 164.67M common shares owned by the public and among those 137.26M shares have been available to trade.
The company’s stock has a 5-day price change of 16.22% and 27.53% over the past three months. RVMD shares are trading 60.39% year to date (YTD), with the 12-month market performance up to 73.39% higher. It has a 12-month low price of $15.44 and touched a high of $45.26 over the same period. RVMD has an average intraday trading volume of 1.35 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 16.88%, 17.57%, and 49.46% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Revolution Medicines Inc (NASDAQ: RVMD) shares accounts for 82.63% of the company’s 164.67M shares outstanding.
It has a market capitalization of $7.59B and a beta (3y monthly) value of 1.45. The earnings-per-share (ttm) stands at -$3.76. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.85% over the week and 4.33% over the month.
Earnings per share for the fiscal year are expected to increase by 18.72%, and -13.94% over the next financial year.
Looking at the support for the RVMD, a number of firms have released research notes about the stock. Barclays stated their Overweight rating for the stock in a research note on July 12, 2024, with the firm’s price target at $52. Jefferies coverage for the Revolution Medicines Inc (RVMD) stock in a research note released on July 08, 2024 offered a Buy rating with a price target of $63. Needham was of a view on April 12, 2024 that the stock is Buy, while Raymond James gave the stock Strong Buy rating on April 10, 2024, issuing a price target of $36- $48. Piper Sandler on their part issued Overweight rating on March 11, 2024.
